Rezolute (NASDAQ:RZLT) PT Lowered to $7.00

Rezolute (NASDAQ:RZLTGet Free Report) had its price objective dropped by analysts at JMP Securities from $8.00 to $7.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock.

Several other brokerages have also recently weighed in on RZLT. Cantor Fitzgerald restated an “overweight” rating and set a $5.00 target price on shares of Rezolute in a report on Tuesday, September 19th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Monday, September 18th.

View Our Latest Stock Report on RZLT

Rezolute Price Performance

Shares of RZLT stock opened at $0.75 on Tuesday. The business has a fifty day moving average of $1.13 and a 200 day moving average of $1.63. The firm has a market capitalization of $27.66 million, a price-to-earnings ratio of -0.69 and a beta of 2.01. Rezolute has a 1 year low of $0.72 and a 1 year high of $2.90.

Rezolute (NASDAQ:RZLTGet Free Report) last posted its earnings results on Thursday, September 14th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.11. As a group, equities research analysts expect that Rezolute will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in shares of Rezolute during the 4th quarter worth $32,000. FMR LLC purchased a new stake in Rezolute during the first quarter worth about $39,000. Renaissance Technologies LLC acquired a new position in Rezolute during the second quarter worth about $58,000. Charles Schwab Investment Management Inc. purchased a new position in Rezolute in the fourth quarter valued at about $67,000. Finally, State Street Corp acquired a new stake in shares of Rezolute during the 1st quarter valued at approximately $69,000. Institutional investors and hedge funds own 65.79% of the company’s stock.

About Rezolute

(Get Free Report)

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Featured Stories

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with's FREE daily email newsletter.